The scientific focus adapted
to express the optimum potential
of your molecule

Marketing:
Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Discovery:
Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex launches the Diet-Induced NASH (DIN) hamster, a unique model showing the same benefits and side effects of obeticholic acid observed in humans.

News detail

Return to all news & events

11/18/2016 Physiogenex launches the Diet-Induced NASH (DIN) hamster, a unique model showing the same benefits and side effects of obeticholic acid observed in humans.

Physiogenex now provides the Diet-Induced NASH (DIN) hamster model, a unique model showing the same benefits and side effects (higher LDL-c, lower HDL-c) of obeticholic acid observed in humans. Compare to mouse models, this predictive model is a robust tool to evaluate novel compounds targeting NASH, in comparison with the benchmark obeticholic acid, a FXR agonist.

Check the technical information about this unique model.

Contact us to get more information for running a DIN hamster study.